Flavivirus vaccine

US11931406B2 · kind B2 · utility

Assignees

• CureVac SE · DE
• Sanofi Pasteur, Inc. · US

Inventors

• Patrick BAUMHOF · Dußlingen, DE
• Wolfgang GROSSE · Tübingen, DE
• Edith JASNY · Stuttgart, DE
• Thomas Kramps · Bellinzona, CH
• Daniel Voss · Tübingen, DE
• Julia DANNENMAIER · Tübingen, DE
• Valérie Lecouturier · Écully, FR
• Yves Girerd-Chambaz · Messimy, FR

Key dates

• Filing date: Dec 12, 2018
• Grant date: Mar 19, 2024
• Expiry date: Mar 16, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.